Chromosomal aberrations in childhood acute lymphoblastic leukemia: 15-year single center experience

Jarošová, Marie; Volejnikova, Jana; Porizkova, Ilona; Holzerová, Milena; Pospı́šilová, Dagmar; Novák, Zbyněk; Vrbková, Jana; Mihál, Vladimı́r

doi:10.1016/j.cancergen.2016.06.004

Cited by 11 publications

(8 citation statements)

References 36 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Philadelphia chromosome‐positive status impacts prognosis and treatment stratification in childhood acute lymphoblastic leukaemia (Ph+ ALL). It is present in 2%‐5% of paediatric ALL and about 25%‐ 40% of adult ALL cases . Children with Ph+ ALL were included in the high‐risk group (HRG) due to a poor outcome despite intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT).…”

Section: Introductionmentioning

confidence: 99%

“…It is present in 2%-5% of paediatric ALL and about 25%-40% of adult ALL cases. [1][2][3] Children with Ph+ ALL were included in the high-risk group (HRG) due to a poor outcome despite intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). The disease-free survival (DFS) using chemotherapy was reported at 25%, and allogeneic HSCT from a matched related donor during the first remission increased DFS to 40%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics and analysis of treatment result in children with Ph‐positive acute lymphoblastic leukaemia in Poland between 2005 and 2017

Zawitkowska

Lejman

Zaucha‐Prażmo

et al. 2018

European J of Haematology

View full text Add to dashboard Cite

Objective The aim of this study was to analyse the clinical characteristics and outcome of children diagnosed with Ph+ ALL. Material and Methods A total of 2591 newly diagnosed ALL children were treated in Poland between the years 2005 and 2017. Of those, 44 were diagnosed with Ph(+) ALL. The patients were treated according to protocols: ALL IC‐BFM 2002 and 2009 (26 patients), EsPhALL (12 patients), initially ALL IC‐BFM and then EsPhALL (6 patients). Results The median of follow‐up in the observed group was 3 years. Overall survival (OS) and event‐free survival (EFS) of Ph+ ALL group were 0.73 and 0.64. OS and EFS of patients after HSCT were 0.78 and 0.66, while without HSCT were 0.6 and 0.6, P = 0.27 and 0.63. OS was 0.8 for patients treated with chemotherapy plus imatinib and 0.61 for chemotherapy alone, P = 0.22, while EFS was 0.66 (imatinib therapy) and 0. 61 (without imatinib), P = 0.41. Conclusion Our study suggests that adding imatinib to intensive chemotherapy seems to improve outcome. However, this study was limited by a small number of patients and a variety of chemotherapy regimens with or without imatinib.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and analysis of treatment result in children with Ph‐positive acute lymphoblastic leukaemia in Poland between 2005 and 2017

Zawitkowska

Lejman

Zaucha‐Prażmo

et al. 2018

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The deletion is found in 9 cases ALL -0.08% of all ALL cases with an abnormal karyotype: 3 cases with T-ALL (Schoch et al, 1996;Jarosova et al, 2016), 5 cases with B-ALL (Kristofferson et al, 1985;Pui et al, 1990;Pui et al, 1992;Ivanov Ofverholm et al, 2016) and 1 case without data on the cell phenotype (Prigogina et al, 1988). The patients with T-cell phenotype are males.…”

Section: Deletion Of Band 1p32 Disease: Acute Lymphoblastic Leukemia/mentioning

confidence: 99%

TAL1 (1p32) deletion in lymphoid malignancies

Mitev¹,

Grahlyova²

2020

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

show abstract

“…The chromosomal gain is most often seen with chromosomes 4, 6, 10, 14, 17, 18, 21 and X [ 13 ] and least seen with chromosomes 1, 2 and 3 [ 14 ]. The overall prognosis is excellent [ 15 ]. However, extra number of specific chromosomes show different prognostic significance.…”

Section: B-all Cytogentic Abnormalitties and Subclassificationmentioning

confidence: 99%

B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy

et al. 2017

View full text Add to dashboard Cite

B lymphoblastic leukemia/lymphoma (B-ALL) is a clonal hematopoietic stem cell neoplasm derived from B-cell progenitors, which mostly occurs in children and adolescents and is regarded as one of top leading causes of death related to malignancies in this population. Despite the majority of patients with B-ALL have fairly good response to conventional chemotherapeutic interventions followed by hematopoietic stem cell transplant for the last decades, a subpopulation of patients show chemo-resistance and a high relapse rate. Adult B-ALL exhibits similar clinical course but worse prognosis in comparison to younger individuals. Ample evidences have shown that the clinical behavior, response rate and clinical outcome of B-ALL rely largely on its genetic and molecular profiles, such as the presence of BCR-ABL1 fusion gene which is an independent negative prognostic predictor. New B-ALL subtypes have been recognized with recurrent genetic abnormalities, including B-ALL with intrachromosomal amplification of chromosome 21 (iAMP21), B-ALL with translocations involving tyrosine kinases or cytokine receptors (“BCR-ABL1-like ALL”). Genome-wide genetic profiling studies on B-ALL have extended our understanding of genomic landscape of B-ALL, and genetic mutations involved in various key pathways have been illustrated. These include CRLF2 and PAX5 alterations, TP53, CREBBP and ERG mutations, characteristic genetic aberrations in BCR-ABL1-like B-ALL and others. The review further provides new insights into clinical implication of the genetic aberrations in regard to targeted therapy development.

show abstract

Chromosomal aberrations in childhood acute lymphoblastic leukemia: 15-year single center experience

Cited by 11 publications

References 36 publications

Clinical characteristics and analysis of treatment result in children with Ph‐positive acute lymphoblastic leukaemia in Poland between 2005 and 2017

Clinical characteristics and analysis of treatment result in children with Ph‐positive acute lymphoblastic leukaemia in Poland between 2005 and 2017

TAL1 (1p32) deletion in lymphoid malignancies

B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy

Contact Info

Product

Resources

About